Design Highlights
- Novartis and Henrietta Lacks’ estate reached a confidential settlement in February 2026 regarding the unauthorized use of HeLa cells.
- The lawsuit, initiated in August 2024, accused Novartis and Viatris of profiting from HeLa cells without consent from Lacks’ family.
- HeLa cells, taken from Lacks in 1951, contributed significantly to medical breakthroughs, including the polio vaccine and cancer research.
- The settlement highlights ongoing ethical issues in biomedical industries, particularly regarding consent and exploitation of marginalized individuals.
- Lacks’ estate continues to pursue legal action against other companies, emphasizing accountability and the need for ethical practices in research.
In a surprising turn of events, Novartis and the estate of Henrietta Lacks reached a confidential settlement, finally putting an end to their legal feud over the unauthorized use of HeLa cells. Yep, you read that right. After years of back-and-forth, they’ve managed to wrap it up in a neat little package. The agreement was finalized in federal court in Maryland back in February 2026, bringing an end to a legal saga that highlighted some serious ethical lapses in the biomedical field.
The lawsuit, which kicked off in August 2024, accused Novartis and Viatris of raking in profits from HeLa cells without ever bothering to ask for permission. Talk about a lack of manners. The estate sought full net profits from the commercialization of these cells, arguing that it was all about unjust enrichment stemming from cells taken without consent.
The estate accused Novartis and Viatris of profiting from HeLa cells without consent, demanding full net profits for unjust enrichment.
This case wasn’t just a one-off; it was part of a broader wave of litigation aimed at holding biomedical companies accountable for their actions. Lacks’ estate has filed additional lawsuits against other companies as well, underscoring the ongoing fight for justice.
HeLa cells, taken from Lacks’ tumor back in 1951, became the first immortal human cell line, thanks to scientist George Otto Gey. These cells have been the unsung heroes behind major medical breakthroughs, including the polio vaccine. HeLa cells have also been vital for cancer research and supported COVID-19 studies, highlighting their ongoing significance in the medical field.
Yet, Lacks herself died of cervical cancer at just 31, buried in an unmarked grave. It’s a grim reminder of how her cells became a gold mine for others while her family remained in the shadows.
While the Novartis settlement is a step forward, it doesn’t mean the estate’s fight is over. They’re still pursuing claims against Viatris, and there’s a separate lawsuit against Ultragenyx for allegedly using HeLa cells in gene therapy. The estate is not backing down, seeking both accountability and full profits. They’ve got a history of this; just last year, they managed to reach an undisclosed agreement with Thermo Fisher for similar reasons. Prompt reporting of incidents and thorough documentation have been crucial elements in building the estate’s case against these companies.
Novartis, a Swiss pharmaceutical giant, benefited from Lacks’ cells without any profit-sharing with her family. Johns Hopkins, where the cells were originally taken, has never sold or profited from them.
It’s a messy situation, one that underscores the long-standing issues of exploitation within a system that has often turned a blind eye to racial injustices in medicine. The settlements are a small but significant step in addressing the decades of benefits derived from Lacks’ stolen cells, and they might just be the wake-up call the industry needs.
